• OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA (22.07.2026)
  • A Leap into the World of Big Pharma (08.07.2026)